Update: Drug shortages business opportunity gains steam

I liked getting mail when I was a kid, and it's the same today. Thanks to all who wrote in support of my editorial last week on the possibility of a business opportunity: a drug manufacturing niche addressing ongoing shortages.

CEOs, presidents, the principal at a consulting and sourcing company and a VP for business strategy from companies in the U.S., U.K, Italy and China are among those who wrote. They offered pharma- or business-related services and insights--including help with the business plan and with making connections--or they expressed that the drug-shortage niche had occurred as a business opportunity to them, too.

Fortified with this support, I'm now plying my editorial sources for manufacturing, business, regulatory and IP to get their read.

More reports as developments arise. In the meantime, keep the e-mails coming. - George Miller


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.